{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"4"},{"groupId":"OG012","value":"49"},{"groupId":"OG013","value":"52"},{"groupId":"OG014","value":"40"},{"groupId":"OG015","value":"45"},{"groupId":"OG016","value":"52"},{"groupId":"OG017","value":"53"},{"groupId":"OG018","value":"35"},{"groupId":"OG019","value":"41"},{"groupId":"OG020","value":"40"},{"groupId":"OG021","value":"48"},{"groupId":"OG022","value":"29"},{"groupId":"OG023","value":"26"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"4"},{"groupId":"OG012","value":"56"},{"groupId":"OG013","value":"57"},{"groupId":"OG014","value":"50"},{"groupId":"OG015","value":"51"},{"groupId":"OG016","value":"60"},{"groupId":"OG017","value":"62"},{"groupId":"OG018","value":"49"},{"groupId":"OG019","value":"49"},{"groupId":"OG020","value":"48"},{"groupId":"OG021","value":"49"},{"groupId":"OG022","value":"36"},{"groupId":"OG023","value":"35"}],"units":"Participants"}],"description":"Number of participants who died during the study.","groups":[{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.1 mg/kg every 2 weeks","id":"OG000","title":"Cohort 1 Uninfected HCC: Treatment 1"},{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.3 mg/kg every 2 weeks","id":"OG001","title":"Cohort 1 Uninfected HCC: Treatment 2"},{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 1 mg/kg every 2 weeks","id":"OG002","title":"Cohort 1 Uninfected HCC: Treatment 3"},{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 3 mg/kg every 2 weeks","id":"OG003","title":"Cohort 1 Uninfected HCC: Treatment 4"},{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 10 mg/kg every 2 weeks","id":"OG004","title":"Cohort 1 Uninfected HCC: Treatment 5"},{"description":"Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 0.3 mg/kg every 2 weeks","id":"OG005","title":"Cohort 1 HCV Infected: Treatment 6"},{"description":"Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 1 mg/kg every 2 weeks","id":"OG006","title":"Cohort 1 HCV Infected: Treatment 7"},{"description":"Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 3 mg/kg every 2 weeks","id":"OG007","title":"Cohort 1 HCV Infected: Treatment 8"},{"description":"Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.1 mg/kg every 2 weeks","id":"OG008","title":"Cohort 1 HBV Infected: Treatment 9"},{"description":"Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.3 mg/kg every 2 weeks","id":"OG009","title":"Cohort 1 HBV Infected: Treatment 10"},{"description":"Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 1 mg/kg every 2 weeks","id":"OG010","title":"Cohort 1 HBV Infected: Treatment 11"},{"description":"Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 3 mg/kg every 2 weeks","id":"OG011","title":"Cohort 1 HBV Infected: Treatment 12"},{"description":"Dose Expansion: Uninfected hepatocellular carcinoma (HCC) participants who are sorafenib naive/intolerant received nivolumab 3 mg/kg every 2 weeks","id":"OG012","title":"Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1"},{"description":"Dose Expansion: Uninfected hepatocellular carcinoma (HCC) participants who are sorafenib progressors received nivolumab 3 mg/kg every 2 weeks","id":"OG013","title":"Cohort 2 Uninfected Sorafenib Progressors: Treatment 2"},{"description":"Dose Expansion: Hepatitis C (HCV)-infected participants received nivolumab 3 mg/kg every 2 weeks","id":"OG014","title":"Cohort 2 HCV Infected: Treatment 3"},{"description":"Dose Expansion: Hepatitis B (HBV)-infected participants received nivolumab 3 mg/kg every 2 weeks","id":"OG015","title":"Cohort 2 HBV Infected: Treatment 4"},{"description":"Arm A: Advance hepatocellular carcinoma (HCC) participants received nivolumab 240 mg every 2 weeks","id":"OG016","title":"Cohort 3: Treatment 1"},{"description":"Arm B: Advance hepatocellular carcinoma (HCC) participants received Sorafenib 400 mg twice a day","id":"OG017","title":"Cohort 3: Treatment 2"},{"description":"Arm A: Participants received nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks","id":"OG018","title":"Cohort 4: Treatment 1"},{"description":"Arm B: Participants received nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks","id":"OG019","title":"Cohort 4: Treatment 2"},{"description":"Arm C: Participants received nivolumab 3 mg/kg every 2 weeks + ipilimumab 1 mg/kg every 6 weeks","id":"OG020","title":"Cohort 4: Treatment 3"},{"description":"Participants received nivolumab 240 mg every 2 weeks","id":"OG021","title":"Cohort 5: Treatment 1"},{"description":"Participants received nivolumab 240 mg every 2 weeks + cabozantinib 40 mg once daily","id":"OG022","title":"Cohort 6: Treatment 1"},{"description":"Participants received nivolumab 3 mg/kg every 2 weeks + ipilimumab 1 mg/kg every 6 weeks + cabozantinib 40 mg once daily","id":"OG023","title":"Cohort 6: Treatment 2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose of study medication until study closure (Up to approximately 144 months)","title":"Number of Participants Who Died","type":"PRIMARY","unitOfMeasure":"Participants"}